Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines
Most anticancer treatments carry a risk for infusion reactions (IRs); incidence may increase when different agents are administered concomitantly. IRs are either allergic reactions to foreign proteins [generally immunoglobulin E (IgE)-mediated allergic responses] or non-immune-mediated reactions. Mo...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
13 July 2017
|
| In: |
Annals of oncology
Year: 2017, Volume: 28, Pages: iv100-iv118 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdx216 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1093/annonc/mdx216 Verlag, Volltext: https://academic.oup.com/annonc/article/28/suppl_4/iv100/3958152 
|
| Author Notes: | S. Roselló, I. Blasco, L. García Fabregat, A. Cervantes, K. Jordan |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 157211732X | ||
| 003 | DE-627 | ||
| 005 | 20220814115503.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180418s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdx216 |2 doi | |
| 035 | |a (DE-627)157211732X | ||
| 035 | |a (DE-576)50211732X | ||
| 035 | |a (DE-599)BSZ50211732X | ||
| 035 | |a (OCoLC)1341007295 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Roselló, Susana |e VerfasserIn |0 (DE-588)1156346061 |0 (DE-627)1019126566 |0 (DE-576)502120819 |4 aut | |
| 245 | 1 | 0 | |a Management of infusion reactions to systemic anticancer therapy |b ESMO Clinical Practice Guidelines |c S. Roselló, I. Blasco, L. García Fabregat, A. Cervantes, K. Jordan |
| 264 | 1 | |c 13 July 2017 | |
| 300 | |a 19 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.04.2018 | ||
| 520 | |a Most anticancer treatments carry a risk for infusion reactions (IRs); incidence may increase when different agents are administered concomitantly. IRs are either allergic reactions to foreign proteins [generally immunoglobulin E (IgE)-mediated allergic responses] or non-immune-mediated reactions. Most IRs are mild with symptoms such as chills, fever, nausea, headache, skin rash, pruritus, etc. Severe reactions are less frequent and may be fatal without appropriate intervention. It is difficult to evaluate these reactions through prospective randomised studies because of the unexpected nature of these events. There is a lack of consensus in the terminology or grading of the severity of an IR in the medical literature. | ||
| 700 | 1 | |a Jordan, Karin |d 1974- |e VerfasserIn |0 (DE-588)123243327 |0 (DE-627)706224078 |0 (DE-576)293619174 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 28(2017), Suppl. 4, Seite iv100-iv118 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Management of infusion reactions to systemic anticancer therapy ESMO Clinical Practice Guidelines |
| 773 | 1 | 8 | |g volume:28 |g year:2017 |g supplement:Suppl. 4 |g pages:iv100-iv118 |g extent:19 |a Management of infusion reactions to systemic anticancer therapy ESMO Clinical Practice Guidelines |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdx216 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/annonc/article/28/suppl_4/iv100/3958152 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180418 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 123243327 |a Jordan, Karin |m 123243327:Jordan, Karin |d 910000 |d 910100 |e 910000PJ123243327 |e 910100PJ123243327 |k 0/910000/ |k 1/910000/910100/ |p 5 |y j | ||
| 999 | |a KXP-PPN157211732X |e 3006353803 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["157211732X"],"doi":["10.1093/annonc/mdx216"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"19 S."}],"note":["Gesehen am 18.04.2018"],"relHost":[{"disp":"Management of infusion reactions to systemic anticancer therapy ESMO Clinical Practice GuidelinesAnnals of oncology","recId":"320428796","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1990 -"],"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"origin":[{"dateIssuedKey":"1990","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-"}],"title":[{"title":"Annals of oncology","title_sort":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology"}],"part":{"volume":"28","text":"28(2017), Suppl. 4, Seite iv100-iv118","pages":"iv100-iv118","extent":"19","year":"2017"},"id":{"eki":["320428796"],"zdb":["2003498-2"],"issn":["1569-8041"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"]}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"13 July 2017"}],"name":{"displayForm":["S. Roselló, I. Blasco, L. García Fabregat, A. Cervantes, K. Jordan"]},"recId":"157211732X","person":[{"family":"Roselló","given":"Susana","display":"Roselló, Susana","role":"aut"},{"given":"Karin","display":"Jordan, Karin","family":"Jordan","role":"aut"}],"title":[{"title_sort":"Management of infusion reactions to systemic anticancer therapy","subtitle":"ESMO Clinical Practice Guidelines","title":"Management of infusion reactions to systemic anticancer therapy"}],"language":["eng"]} | ||
| SRT | |a ROSELLOSUSMANAGEMENT1320 | ||